2.2.4 Vatelizumab Vatelizumab (SAR339658), a monoclonal antibody targeting 47 integrin, was evaluated in a double-blind, placebo-controlled Phase 2 RCT (NCT01659138) involving patients aged 1870 with moderate to severe UC who had inadequate response to immunosuppressants or TNF antagonists, confirmed by MS 612 and MES 2 with fecal calprotectin 200mg/kg
However, you should reach out to your healthcare provider if bloating is severe enough to interfere with daily activities, prevents you from eating adequate protein or calories, or is accompanied by vomiting, severe pain, or constipation lasting more than a few days
I also learned that I have no Native American heritage whatsoeverdespite the fact that myself, my mother, and her mother were all raised believing we were part Cherokee
You can go back to your regular daily activities immediately after the treatment